NCT05768230View on ClinicalTrials.gov

Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Transesophageal EchocardiographyAcute Respiratory Distress SyndromeRight Ventricular Dysfunction
Interventions
DRUG

levosimendan

Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h

DRUG

5% glucose injection

5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h

Trial Locations (1)

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05768230 - Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV | Biotech Hunter | Biotech Hunter